NSE filing, NSE: TATVA. Summary written from the filing by ALFA Finder's alert engine.
Tatva Chintan Pharma Chem Ltd: key numbers
- Share price
- ₹1,627.80
- Market cap
- ₹3,808 Cr
- Revenue (annual)
- ₹505.9 Cr
- Net profit (annual)
- ₹42.05 Cr
- P/E (TTM)
- 60.5×Sector 34.1×
- Promoter holding
- 72.02%+0.00% QoQ
- FII holding
- 4.38%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tatva Chintan Pharma Chem Ltd
All →Tatva Chintan Pharma Chem Investor Presentation: Key Takeaways
Tatva Chintan reported record quarterly revenue of ₹2,173 Mn for Q2 FY27, up 76% YoY, driven by strong SDA demand. EBITDA margins remained flat at 19% due to high solvent costs and freight spikes.
Tatva Chintan Pharma Chem Q2 FY27 Results: Net Profit ₹21.5 Cr, Up 117.2% YoY
Tatva Chintan Pharma Chem Ltd reported revenue from operations of ₹217.3 Cr (+76.0% YoY) and net profit of ₹21.5 Cr (+117.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹21.5 Cr · +117.2% YoY
Tatva Chintan Pharma Chem Other Announcement
The company has filed its quarterly shareholding pattern as per SEBI regulations. This routine disclosure provides details on the current shareholding structure.
Tatva Chintan Pharma Chem Board Meeting Date
Tatva Chintan Pharma Chem has scheduled a Board meeting for 19 October 2026 to consider Q1 FY27 financial results. The trading window will remain closed until 48 hours after results are published.
Tatva Chintan Pharma Chem Annual General Meeting
The company held its 30th Annual General Meeting on September 25, 2026. Shareholders considered and approved items including financial statements and director re-appointments.
Tatva Chintan Pharma Chem Business Update
Tatva Chintan Pharma Chem Limited submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report highlights its specialty chemicals operations and ESG metrics.
Other credit rating announcements
All →GSPL Transmission Credit Rating
CARE Ratings assigned GSPL Transmission a CARE AA+ rating on bank facilities with a stable outlook. The rating cites nil debt and strong liquidity.
Meghmani Organics Credit Rating
India Ratings assigned Meghmani Organics' bank loan facilities of INR 11,000 million a rating of IND A/Stable/IND A1. The filing encloses the rating letter and a facilities breakup.
JSW Cement Credit Rating
CRISIL reaffirmed JSW Cement's long-term rating at AA-/Stable and its short-term ratings at A1+. No new borrowing or fund raise is announced.
Tejas Networks Credit Rating
ICRA reaffirmed Tejas Networks' [ICRA]A+(Stable) long-term rating and [ICRA]A1+ short-term rating. The rating covers Rs.6,000 Crore of credit facilities and a Rs.500 Crore CP programme.
HDB Financial Services Credit Rating
CARE Ratings reaffirmed HDB Financial Services' AAA rating with Stable outlook across its debt instruments. Its A1+ short-term rating was also reaffirmed.
Asian Energy Services Credit Rating
Asian Energy Services Limited disclosed that CRISIL maintained its 'Watch Developing' rating on INR 317.5 Crore of bank facilities. The watch continues pending final Ministry of Petroleum approval for the merger of its parent, Oilmax Energy.